BlackRock Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$39K	Buy	8,163 +323	+4%	+$1.76K	﹤0.01%	3312
2016 Q3	$52K	Buy	7,840 +2,349	+43%	+$12.5K	﹤0.01%	3237
2016 Q2	$30K	Buy	5,491 +49	+0.9%	+$781	﹤0.01%	3352
2016 Q1	$116K	Buy	5,442 +499	+10%	+$11.2K	﹤0.01%	2848
2015 Q4	$156K	Sell	4,943 -248	-5%	-$8.76K	﹤0.01%	2706
2015 Q3	$179K	Buy	5,191 +214	+4%	+$6.47K	﹤0.01%	2787
2015 Q2	$157K	Buy	4,977 +841	+20%	+$24.8K	﹤0.01%	2939
2015 Q1	$121K	Buy	4,136 +1,434	+53%	+$33.6K	﹤0.01%	2950
2014 Q4	$50K	Sell	2,702 -273	-9%	-$4.6K	﹤0.01%	3276
2014 Q3	$52K	Hold	2,975	–	–	﹤0.01%	3259
2014 Q2	$60K	Buy	+2,975	New	+$57.4K	﹤0.01%	3224

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's MRTX Position: Q4 2016 in Review

BlackRock Advisors increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 4.1% in Q4 2016, buying an estimated $1.76K and bringing the position to 8,163 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

BlackRock Advisors first reported a position in MRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $179K in Q3 2015. 62 funds tracked by Wall St. Rank hold MRTX as of Q4 2016.

BlackRock Advisors held 8,163 shares of Mirati Therapeutics, Inc. Common Stock worth $39K as of Q4 2016.
BlackRock Advisors bought 323 Mirati Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $1.76K.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3312 holding.
BlackRock Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 11 quarters since.
BlackRock Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $179K in Q3 2015.
62 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.